EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders

Alessandro Bonifazi iD, Fabio Del Bello iD, Gianfabio Giorgioni iD, Alessandro Piergentili iD, Elizabeth Saab iD, Luca Botticelli iD, Carlo Cifani iD, Emanuela Micioni Di Bonaventura iD, Maria Vittoria Micioni Di Bonaventura iD, Wilma Quaglia iD

Medicinal Research Reviews · 2023

DOI: 10.1002/med.21959 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, 2023. Verfasst von Alessandro Bonifazi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse - Intramural Research Program, Nati…. Hauptthemen laut MEDLINE: Neuropeptides. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 229 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Orexin‐A and orexin‐B, also named hypocretin‐1 and hypocretin‐2, are two hypothalamic neuropeptides highly conserved across mammalian species. Their effects are mediated by two distinct G protein‐coupled receptors, namely orexin receptor type 1 (OX1‐R) and type 2 (OX2‐R), which share 64% amino acid identity. Given the wide expression of OX‐Rs in different central nervous system and peripheral areas and the several pathophysiological functions in which they are involved, including sleep‐wake cycle regulation (mainly mediated by OX2‐R), emotion, panic‐like behaviors, anxiety/stress, food intake, and energy homeostasis (mainly mediated by OX1‐R), both subtypes represent targets of interest for many structure–activity relationship (SAR) campaigns carried out by pharmaceutical companies and academies. However, before 2017 the research was predominantly directed towards dual‐orexin ligands, and limited chemotypes were investigated. Analytical characterizations, including resolved structures for both OX1‐R and OX2‐R in complex with agonists and antagonists, have improved the understanding of the molecular basis of receptor recognition and are assets for medicinal chemists in the design of subtype‐selective ligands. This review is focused on the medicinal chemistry aspects of small molecules acting as dual or subtype selective OX1‐R/OX2‐R agonists and antagonists belonging to different chemotypes and developed in the last years, including radiolabeled OX‐R ligands for molecular imaging. Moreover, the pharmacological effects of the most studied ligands in different neuropsychiatric diseases, such as sleep, mood, substance use, and eating disorders, as well as pain, have been discussed. Poly‐pharmacology applications and multitarget ligands have also been considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuropeptidesHumansAnimalsOrexin ReceptorsLigandsOrexinsReceptors, G-Protein-CoupledCentral Nervous SystemReceptors, NeuropeptideMammals

Stichwörter der Autor:innen

dual OX-R ligandsneuropsychiatric disordersorexin receptorspoly-pharmacologyselective agonists or antagonists

Substanzen

Orexin ReceptorsLigandsOrexinsNeuropeptidesReceptors, G-Protein-CoupledReceptors, Neuropeptide

Autor:innen und Institutionen

  • Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health, Baltimore, Maryland, United States.
  • School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Camerino, Italy.
  • School of Pharmacy, Pharmacology Unit, University of Camerino, Camerino, Italy.

ORCID-Profile: Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, Alessandro Piergentili, Elizabeth Saab, Luca Botticelli, Carlo Cifani, Emanuela Micioni Di Bonaventura, Maria Vittoria Micioni Di Bonaventura, Wilma Quaglia

Zitieren

APA

Bonifazi, A., Del Bello, F., Giorgioni, G., Piergentili, A., Saab, E., Botticelli, L., Cifani, C., Micioni Di Bonaventura, E., Micioni Di Bonaventura, M. V., & Quaglia, W. (2023). Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders. Medicinal Research Reviews. https://doi.org/10.1002/med.21959

Vancouver

Bonifazi A, Del Bello F, Giorgioni G, Piergentili A, Saab E, Botticelli L, et al. Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders. Medicinal Research Reviews. 2023. doi:10.1002/med.21959

BibTeX
@article{Bonifazi2023,
  author = {Bonifazi, Alessandro and Del Bello, Fabio and Giorgioni, Gianfabio and Piergentili, Alessandro and Saab, Elizabeth and Botticelli, Luca and Cifani, Carlo and Micioni Di Bonaventura, Emanuela and Micioni Di Bonaventura, Maria Vittoria and Quaglia, Wilma},
  title = {Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders},
  journal = {Medicinal Research Reviews},
  year = {2023},
  doi = {10.1002/med.21959}
}
Kostenlos starten →